KROS
Keros Therapeutics Inc.
$15.56
-$0.48(-2.99%)
41
Overall
--
Value
40
Tech
42
Quality
Market Cap
$641.72M
Volume
562.76K
52W Range
$9.12 - $72.37
Target Price
$23.33
Order:
Income Statement
| Metric | Trend | Chart | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|
| REVENUE | |||||||
| Total Revenue | -- | $20.1M | -- | $151.0K | $3.5M | ||
| Total Revenue | -- | $20.1M | -- | $151.0K | $3.5M | ||
| GROSS PROFIT | |||||||
| Gross Profit | -- | $20.1M | -- | $151.0K | $3.5M | ||
| OPERATING EXPENSES | |||||||
| Operating Expenses | $46.7M | $76.5M | $107.7M | $170.1M | $214.4M | ||
| Research & Development | $33.9M | $55.1M | $87.3M | $135.3M | $173.6M | ||
| Research Expense | $33.9M | $55.1M | $87.3M | $135.3M | $173.6M | ||
| Selling, General & Administrative | $12.8M | $21.3M | $27.5M | $34.8M | $40.8M | ||
| General & Administrative Expenses | $12.8M | $21.3M | $27.5M | $34.8M | $40.8M | ||
| Salaries & Wages | -- | -- | $18.7M | $28.8M | $34.9M | ||
| Depreciation & Amortization | $300.0K | $400.0K | $700.0K | $815.0K | $1.2M | ||
| Depreciation & Amortization | $300.0K | $400.0K | $700.0K | $815.0K | $1.2M | ||
| Other Operating Expenses | $468.0K | $600.0K | $1.6M | $4.3M | $-1.1M | ||
| OPERATING INCOME | |||||||
| Operating income | $-46.7M | $-56.4M | $-114.8M | $-169.9M | $-210.8M | ||
| EBITDA | $-45.2M | $-56.4M | $-103.1M | $-150.6M | $-184.0M | ||
| NON-OPERATING ITEMS | |||||||
| Interest Expense (Non-Operating) | $6.0K | $4.0K | $1.0K | -- | -- | ||
| Intinc | $-6.0K | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-6.0K | $-4.0K | $-1.0K | -- | -- | ||
| Other Income/Expense | $-1.2M | $356.0K | $3.0M | $206.0K | $954.0K | ||
| Other Special Charges | $2.7M | $-356.0K | $-613.0K | $-206.0K | $-954.0K | ||
| SPECIAL ITEMS | |||||||
| Special Income Charges | -- | -- | $3.6M | $14.8M | $23.5M | ||
| PRE-TAX INCOME | |||||||
| EBIT | $-45.5M | $-56.7M | $-104.7M | $-153.0M | $-187.1M | ||
| Pre-Tax Income | $-45.5M | $-56.7M | $-104.7M | $-153.0M | $-187.1M | ||
| INCOME TAX | |||||||
| Tax Provision | $-172.0K | $2.0M | -- | -- | $300.0K | ||
| NET INCOME | |||||||
| Net Income | $-45.4M | $-58.7M | $-104.7M | $-153.0M | $-187.4M | ||
| Net Income (Continuing Operations) | $-45.4M | $-58.7M | $-104.7M | $-153.0M | $-187.4M | ||
| Net Income (Discontinued Operations) | $-45.4M | $-58.7M | $-104.7M | $-153.0M | $-187.4M | ||
| Net Income (Common Stockholders) | $-45.4M | $-58.7M | $-104.7M | $-153.0M | $-187.4M | ||
| Normalized Income | -- | -- | -- | -- | $-208.7M | ||
| TOTALS | |||||||
| Total Expenses | $46.7M | $76.5M | $107.7M | $170.1M | $214.4M | ||
| SHARE & EPS DATA | |||||||
| Average Shares Outstanding | $15.5M | $23.3M | $25.2M | $29.4M | $37.4M | ||
| Average Shares Outstanding (Diluted) | $15.5M | $23.3M | $25.2M | $29.4M | $37.4M | ||
| Shares Outstanding | $23.3M | $40.6M | $28.5M | $36.0M | $40.6M | ||
| Basic EPS | $-2.93 | $-2.52 | $-4.15 | $-5.2 | $-5 | ||
| Basic EPS (Continuing Operations) | $-2.93 | $-2.52 | $-4.15 | $-5.2 | $-5 | ||
| Diluted EPS | $-2.93 | $-2.52 | $-4.15 | $-5.2 | $-5 | ||
| Diluted EPS (Continuing Operations) | -- | $-2.52 | $-4.15 | $-5.2 | $-5 | ||
| OTHER METRICS | |||||||
| Accrued Preferred Stock Dividends | $45.4M | $58.7M | $104.7M | $153.0M | $187.4M | ||
| Other Gand A | $12.8M | $21.3M | $27.5M | $34.8M | $40.8M | ||
| Otherunder Preferred Stock Dividend | $45.4M | $58.7M | $104.7M | $153.0M | $187.4M | ||
| Preferred Stock Dividends | $45.4M | $58.7M | $104.7M | $153.0M | $187.4M | ||
| Othspecchg | -- | -- | $-3.6M | $-14.8M | $-23.5M | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | KROS | $15.56 | -3.0% | 562.76K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |